GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Intrinsic Value: Projected FCF

MedMira (MedMira) Intrinsic Value: Projected FCF : $-0.03 (As of May. 21, 2024)


View and export this data going back to . Start your Free Trial

What is MedMira Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-21), MedMira's Intrinsic Value: Projected FCF is $-0.03. The stock price of MedMira is $0.06. Therefore, MedMira's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for MedMira's Intrinsic Value: Projected FCF or its related term are showing as below:

MMIRF's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.35
* Ranked among companies with meaningful Price-to-Projected-FCF only.

MedMira Intrinsic Value: Projected FCF Historical Data

The historical data trend for MedMira's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Intrinsic Value: Projected FCF Chart

MedMira Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.05 -0.04 -0.03 -0.03

MedMira Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.03 -0.03 -0.01 -0.02

Competitive Comparison of MedMira's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, MedMira's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedMira's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where MedMira's Price-to-Projected-FCF falls into.



MedMira Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get MedMira's Free Cash Flow(6 year avg) = $-0.80.

MedMira's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Jan24)/0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-0.80176+-11.98/0.8)/698.088
=-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedMira  (OTCPK:MMIRF) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

MedMira's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.06/-0.032385654954076
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedMira Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of MedMira's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (MedMira) Business Description

Industry
Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (MedMira) Headlines

From GuruFocus

MedMira Closes New Equity Investment for Future Growth

By GlobeNewswire GlobeNewswire 07-15-2021

MedMira Reports First Quarter Results FY2023

By ACCESSWIRE ACCESSWIRE 12-31-2022

Progress Update on MedMira's COVID-19 Product Family

By GlobeNewswire GlobeNewswire 01-30-2021

MedMira Receives CE Mark for Its VYRA(TM) COVID-19 Antigen Test

By ACCESSWIRE ACCESSWIRE 10-14-2022

MedMira Reports FY2021 Fourth Quarter and Year End Financial Results

By GlobeNewswire GlobeNewswire 12-01-2021

Progress Update on Securities

By ACCESSWIRE 08-31-2023

MedMira Reports Third Quarter Results FY2023

By ACCESSWIRE 06-30-2023